share_log

Oppenheimer Reiterates Outperform on Eloxx Pharmaceuticals, Maintains $50 Price Target

Benzinga ·  Apr 6, 2023 07:44

Oppenheimer analyst Hartaj Singh reiterates Eloxx Pharmaceuticals (NASDAQ:ELOX) with a Outperform and maintains $50 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment